Recent advances in treatment of medullary thyroid carcinoma

Annales d'Endocrinologie

Volumn 68, Issue 2-3, 2007, Pages 147-153

  Vezzosi, D ^a   Bennet, A ^a   Caron, P ^a  

^a CHU RANGUEIL   (France)

Author keywords

Immunotherapy; Medullary thyroid carcinoma; Radioimmunotherapy; Suicide gene; Tyrosine kinase inhibitors

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIBODY; COTRANSPORTER; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DACARBAZINE; DENDRITIC CELL VACCINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; GANCICLOVIR; IMATINIB; IMMUNOMODULATING AGENT; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 2; PACLITAXEL; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; RIBOZYME; SODIUM IODIDE; THYMIDINE KINASE; CYCLOOXYGENASE 1;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DENDRITIC CELL; DRUG MECHANISM; ERYTHEMA; FAMILIAL CANCER; FEVER; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE TRANSFER; GERM LINE; HERPES SIMPLEX VIRUS 1; HUMAN; INJECTION SITE INDURATION; ISOTOPE LABELING; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE DISSECTION; MONOTHERAPY; NEUTROPENIA; NONHUMAN; PAIN; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; SHORT SURVEY; SUICIDE GENE THERAPY; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; GENE THERAPY; GENETICS; IMMUNOTHERAPY; MEDULLARY CARCINOMA; METABOLISM; PATHOLOGY; REVIEW; SUICIDE TRANSGENE; THYROID TUMOR;

ANIMALS; CARCINOMA, MEDULLARY; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; IMMUNOTHERAPY; IODINE RADIOISOTOPES; PROTO-ONCOGENE PROTEINS C-RET; RADIOIMMUNOTHERAPY; THYROID NEOPLASMS;

EID: 34547737564     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2006.11.004     Document Type: Short Survey

References (51)

1. Bergholm U., Bergstrom R., and Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79 (1997) 132-138
2. Brierley J., Tsang R., Simpson W., et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6 (1996) 305-310
3. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic ret mutants. J. Natl. Cancer Inst. 98 (2006) 326-334
4. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic ret kinases. Cancer Res. 62 (2002) 7284-7290
5. Carniti C., Perego C., Mondellini P., Pierotti M., and Bongarzone I. Pp1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. Cancer Res. 63 (2003) 2234-2243
6. Cengic N., Baker C., Schütz M., et al. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression. J. Clin. Endocrinol. Metab. 90 (2005) 4457-4464
7. Chatal J., Campion L., Kraeber-Bodéré F., et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French endocrine study group. J. Clin. Oncol. 24 (2006) 1705-1711
8. Cohen M., Hussain H., and Molley J. Inhibition of medullary thyroid carcinoma cell proliferation and ret phosphorylation by tyrosine kinase inhibitors. Surgery (2002) 132
9. Dottorini M., Assi A., Sironi M., et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77 (1996) 1556-1565
10. Drosten M., Frilling A., Stiewe T., and Pützer B. A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic rets signalling by adenoviral vector-mediated expression of a dominant-negative ret mutant. Surgery 132 (2002) 9916997
11. Drosten M., Stiewe T., and Pützer B. Antitumor capacity of a dominant-negative ret proto-oncogene mutant in a medullary thyroid carcinoma model. Hum. Gene Ther. 14 (2003) 971-982
12. Druker B., Talpaz M., Resta D., et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. 344 (2001) 1031-1037
13. Eng C. The ret proto-oncogene in the development of human cancer. J. Clin. Oncol. 17 (1999) 380-393
14. Ezzat S., Huang P., Dackiw A., and Asa S. Dual inhibition of ret and FGFR4 restrains medullary thyroid cancer cell growth. Clin. Cancer Res. 11 (2005) 1336-1341
15. Fersht N., Vini L., A'hern R., and Harmer C. The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid 11 (2001) 1161-1168
16. Fromigue J., De Baere T., Baudin E., et al. Chemoembolization for liver metastases from medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 91 (2006) 2496-2499
17. Gimm O., Ukkat J., and Dralle H. Determinative factors of biochemical cure after primary and preoperative surgery for sporadic medullary thyroid carcinoma. World J. Surg. 22 (1998) 562-568
18. Hennige A., Lammers R., Höppner W., et al. Inhibition of ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology 142 (2001) 4441-4447
19. Johanson V., Arvidsson Y., Kölby L., et al. Antitumoral effects of the pyridil cyanoguanidine CHS828 on three different types of neuroendocrine tumours xenografted to nude mice. Neuroendocrinology 82 (2005) 171-176
20. Juweid M., Hajjar G., Stein R., et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14F(ab)2 anti-carcinoembryonic antigen MAB and AHSCR. J. Nucl. Med. 41 (2000) 93-103
21. Juweid M., Hajjar G., Swayne L., et al. Phase I/II trial of 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 85 (1999) 1828-1842
22. Kebebew E., Ituarte P., Siperstein A., Duh Q., and Clark O. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 (2000) 1139-1148
23. Kraeber-Bodéré F., Bardet S., Hoefnagel C., et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin. Cancer Res. 5 (1999) 3190s-3198s
24. Kraeber-Bodéré F., Rousseau C., Bodet-Milin C., et al. Targeting, toxicity and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J. Nucl. Med. 47 (2006) 247-255
25. Kraeber-Bodéré F., Saï-Maurel C., Campion L., et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol. Cancer Ther. 1 (2002) 267-274
26. Lausson S., Fournes B., Borrel C., Milhaud G., and Treilhou-Lahille F. Immune response against medullary thyroid carcinoma (mtc) induced by parental and/or interleukin-2-secreting mtc cells in a rat model of human familial medullary thyroid carcinoma. Cancer Immunol. Immunother. 43 (1996) 116-123
27. Liu Z., Falola J., Zhu X., et al. Antiproliferative effects of src inhibition on medullary thyroid cancer. J. Clin. Endocrinol. Metab. 89 (2004) 3503-3509
28. Minemura K., Takeda T., Minemura K., et al. Cell-specific induction of sensitivity to ganciclovir in medullary thyroid carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Endocrinology 141 (2000) 1814-1822
29. Modigliani E., Cohen R., Joannidis S., et al. Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 36 (1992) 183-186
30. Nocera M., Baudin E., Pellegreti G., et al. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5fu-dacarbazine. Br. J. Cancer 83 (2000) 715-718
31. Parthasarathy R., Cote G., and Gagel R. Hammerhead ribozyme-mediated inactivation of mutant ret in medullary thyroid carcinoma. Cancer Res. 59 (1999) 3911-3914
32. Quidville V., Segond N., Pidoux E., et al. Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase. Endocrinology 145 (2004) 2561-2571
33. Schott M., Seissler J., Lettmann M., et al. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J. Clin. Endocrinol. Metab. 86 (2001) 4965-4969
34. Scollo C., Baudin E., Travagli J., et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 88 (2003) 2070-2075
35. Siegel J., and Puri R. Interleukin-2 toxicity. J. Clin. Oncol. 9 (1991) 694-704
36. Skinner M., Safford S., and Freemerman A. Ret tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of st1571. Anticancer Res. 23 5A (2003) 3601-3606
37. Stein R., Chen S., Reed L., Richel H., and Goldenberg D. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma. Cancer 94 (2002) 51-61
38. Stein R., and Goldenberg D. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacrabazine chemotherapy. Mol. Cancer Ther. 3 (2004) 1559-1564
39. Stift A., Sachet M., Yagubian R., et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin. Cancer Res. 10 (2004) 2944-2953
40. Strock C., Park J., Rosen D., et al. Cep-701 and cep-751 inhibit constitutively activated ret tyrosine kinase activity and block medullary carcinoma cell growth. Cancer Res. 63 (2003) 5559-5563
41. Strock C., Park J., Rosen D., et al. Activity of irinotecan and the tyrosine kinase inhibitor cep-751 in medullary thyroid cancer. J. Clin. Endocrinol. Metab. 91 (2006) 79-84
42. Weeraratna A., Dalrymple S., Lamb J., et al. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin. Cancer Res. 7 (2001) 2237-2245
43. Yamazaki M., Zhang R., Straus F., et al. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of inerleukin-12. Gene Ther. 9 (2002) 64-74
44. Zatelli M., Luchin A., Piccin D., et al. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. 90 (2005) 5754-5760
45. Zatelli M., Piccin D., Tagliati F., et al. Src homology-2-containing cell proliferation in human medullary thyroid carcinoma. Endocrinology 146 (2005) 2692-2698
46. Zhang R., Baunoch D., and Degroot L. Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene. Thyroid 8 (1998) 1137-1146
47. Zhang R., and Degroot L. Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: relationship of bystander effect and antitumor efficacy. Thyroid 10 (2000) 313-319
48. Zhang R., and Degroot L. Genetic immunotherapy of established tumours with adenoviral vectors transducing murine interleukin-12 (mil-12) subunits in a rat medullary thyroid carcinoma model. Clin. Endocrinol. (Oxf.) 52 (2000) 687-694
49. Zhang R., and Degroot L. An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma. Endocr. Relat. Cancer 8 (2001) 315-325
50. Zhang R., Minemura K., and Degroot L. Immunotherapy for medullary thyroid carcinoma by a replication-defective adenovirus transducing murine interleukin-2. Endocrinology 139 (1998) 601-608
51. Zhang R., Straus F., and Degroot L. Effective genetic therapy of established medullary thyroid carcinomas with murine interleukin-2: dissemination and cytotoxicity studies in a rat tumor model. Endocrinology 140 (1999) 2152-2158